The $3 billion project was founded in 1990 by the United States Department of Energy and the U.S. National Institutes of Health, and was expected to take 15 years. Due to widespread international cooperation and advances in the field of genomics (especially in sequence analysis), as well as huge advances in computing technology, a rough draft of the genome was finished in 2000 (announced jointly by US president Bill Clinton and British Prime Minister Tony Blair on June 26, 2000), two years earlier than planned.
The consortium comprised:
Initiation of the Project was the culmination of several years of work supported by the US Department of Energy, in particular a feasibility workshop in 1986 and a subsequent detailed description of the Human Genome Initiative in a report that led to the formal sanctioning of the initiative by the Department of Energy. This 1987 report stated boldly, "The ultimate goal of this initiative is to understand the human genome" and "Knowledge of the human genome is as necessary to the continuing progress of medicine and other health sciences as knowledge of human anatomy has been for the present state of medicine". Though leaders had already been considering technologies required for such an undertaking at least as early as 19852.
Eight years after the HGP was being initiated, an identical quest was initiated separately with private venture capital by a company called Celera Genomics (founded by Craig Venter) while the HGP was still being pursued. Celera Genomics used a newer, albeit riskier technique called shotgun sequencing and proceeded at a faster pace and at a fraction of the cost of the taxpayer-funded project (approximately $3 billion of taxpayer dollars versus about $300 million of private research funding). Celera initially planned to patent all genes found, unlike the gene sequences found by the original publicly-funded HGP, which are in line with the so called Bermuda Statement (Feb 1996) made freely available to the public, 24 hours a day. However, Celera later decided to release its findings to the public after President Clinton announced that that the information could not be patented, sending Celera's stock plummeting and the Nasdaq, paticularly the biotech sector, into a precipitous decline. The competition between the rivals proved to be very good for the Project, and they agreed to pool their data.
Although the working draft was announced in June 2000, it was not until February 2001 that Celera and the HGP scientists published actual details of their drafts. Special issues of Nature (which published the publicly-funded project's scientific paper) and Science (which published Celera's paper) contained descriptions of the methods used to produce the draft sequence, as well as analysis of said sequence. These drafts are hoped to provide a 'scaffold' of about 90% of the genome upon which gaps can be closed.
Each draft sequence has been checked at least four to five times to increase 'depth of coverage' or accuracy. Approximately 47% of the draft were high-quality sequences - the final version will have been checked eight to nine times giving an error rate of just 1 in 10,000 bases.
The human genome project is one of a number of international genome projects in biology, each aimed at sequencing the DNA of a specific organism. While the human DNA sequence offers the most tangible benefits, important developments in biology and medicine are predicted as a result of the sequencing of model organisms including mice, fruitflies, zebrafish, yeast, nematodes and many microbial organisms and parasites.
In October 2004, researchers of the HGP announced a new estimate of 20,000 to 25,000 genes in the human genome. Previously 30,000 to 40,000 had been predicted, while estimates at the start of the project reached up to as high as 100,000.
The goals of the original HGP were not only to determine all 3 billion base pairs in the human genome with a minimal error rate, but also to identify all the genes in this vast amount of data. This part of the project is still ongoing although a preliminary count indicates about 25,000 genes in the human genome, which is far fewer than predicted by most scientists.
Today, the sequence of the human DNA is stored in databases and is available for everyone on the Internet. The U.S. National Center for Bioinformatics (and sister organizations in Europe and Japan) houses the genomic sequence, along with sequences of known and hypothetical genes and proteins. Other organizations such as the University of California, Santa Cruz, and ENSEMBL present additional data and annotation and powerful tools for visualizing and searching through it. Computer programs have been developed to analyse that data, as the data itself is next to useless without interpretation.
The process of identifying the boundaries of genes and other features in raw DNA sequence is called annotation and is the domain of bioinformatics. While expert biologists make the best annotators, such annotation proceeds slowly, and computer programs are increasingly used to meet the high-throughput demands of genome sequencing projects. The best current technologies for annotation make use of statistical models that take advantage of parallels between DNA sequences and human language, using concepts from computer science such as formal grammars.
All humans have unique genomic sequence, as such, the data published by the HGP does not represent the exact sequence of each and every individual's genome. It is the combined genome of a small number of anonymous donors. The HGP genome is a scaffold for future work in identifying differences between individuals. Most of the current effort in identifying differences between individuals involves single nucleotide polymorphisms.
Clear practical results of the project emerged even before the work was finished. For example, a number of companies, such as Myriad Genetics started offering inexpensive and easy to administer genetic tests that can show predisposition to a variety of illnesses, including breast cancer, blood clotting, cystic fibrosis, liver diseases and many others.
There are also many tangible benefits for biological scientists. For example, a researcher investigating a certain form of cancer may have narrowed down his search to a particular gene. By visiting the human genome database on the world-wide web, this researcher can examine what other scientists have written about this gene, including (potentially) its three-dimensional structure, its function(s), its evolutionary relationships to other human genes, or to genes in mice or yeast or fruitflies, possible detrimental mutations, interactions with other genes, body tissues in which this gene is activated, diseases associated with this gene... the list of datatypes is long, one reason why bioinformatics is so challenging.
The work on interpretation of genome data is still in its initial stages. In the future the knowledge gained by the understanding of the genome will boost the fields of medicine and biotechnology, eventually leading to cures for cancer, Alzheimers disease and other diseases.
On a more philosophical level, the analysis of similarities between DNA sequences from different organisms is opening new avenues in the study of evolution. In many cases, evolutionary questions can now be framed in terms of molecular biology; indeed, many major evolutionary milestones (the emergence of the ribosome and organelles, the development of embryos with body plans, the vertebrate immune system) can be related to the molecular level. Many questions about the similarities and differences between humans and our closest relatives (the primates, and indeed the other mammals) are expected to be illuminated by the data from this project.
Note 2: DeLisi, Charles. (2001). Genomes: 15 Years Later A Perspective by Charles DeLisi, HGP Pioneer. Human Genome News, 11(3-4). Retrieved 2005-02-03.